https://www.selleckchem.com/products/dzd9008.html
106). TMB and prevalence of intermediate TMB (TMB-I 6-20 mutations/Mb) were higher in the resistant versus sensitive cohort (median TMB 6 [IQR, 3-7.29] versus 3 [IQR, 1.26-3.5]; P=0.013; TMB-I/H 60% versus 11%; P=0.001). Patients with TMB-I had shorter PFS (3.3 versus 5.9 months; HR=2.19, 95%CI, 1.07-4.47, P=0.031) and overall survival (6.3 versus 10.5 months; HR=2.22, 95%CI, 1.02-4.81, P=0.044). Despite the small sample size, the association of a relatively higher TMB with limited benefit from EGFR/BRAF blockade in patients with MSS an
Like
Comment
Share
